IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: Interaction with their plasma levels

Genes and Immunity

Volumn 2, Issue 4, 2001, Pages 222-228

  Buchs, N ^a   Di Giovine, F S ^c   Silvestri, T ^c   Vannier, E ^b   Duff, G W ^c   Miossec, P ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b TUFTS MEDICAL CENTER   (United States)

^c NONE

Author keywords

Destruction; Gene polymorphism; Interleukin 1; Interleukin 1 receptor antagonist; Rheumatoid arthritis

Indexed keywords

IL1RN PROTEIN, HUMAN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PRIMER DNA; SIALOGLYCOPROTEIN;

ARTICLE; BLOOD; GENETIC POLYMORPHISM; GENETICS; HOSPITALIZATION; HUMAN; NUCLEOTIDE SEQUENCE; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; BASE SEQUENCE; DNA PRIMERS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX; SIALOGLYCOPROTEINS;

EID: 0035375779     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6363766     Document Type: Article

References (38)

1. Deighton CM, Walker DJ, Griffiths ID, Roberts DF. The contribution of HLA to rheumatoid arthritis. Clin Genet 1989; 36: 178-182.
2. Cornelis F, Faure S, Martinez M et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci USA 1998; 95: 10746-10750.
3. Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 1994; 19: 382-384.
4. Arend WP, Dayer JM. Inhibition of the production and effects of Interleukin-1 and Tumor Necrosis Factor a in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151-160.
5. Hopkins SJ, Humphreys M, Jayson MI. Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1. Clin Exp Immunol 1988; 72: 422-427.
6. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988; 2: 706-709.
7. North J, Situnayake RD, Tikly M et al. Interleukin 1 beta, hand and foot bone mineral content and the development of joint erosions in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 543-546.
8. Danis VA, Kulesz AJ, Nelson DS, Brooks PM. The effect of gold sodium thiomalate and auranofin on lipopolysaccharide-induced interleukin-1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis. Clin Exp Immunol 1990; 79: 335-340.
9. Chomarat P, Vannier E, Dechanet J et al. The balance of IL-1 receptor antagonist/IL-1β in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995; 154: 1432-1439.
10. Firestein GS, Boyle DL, Yu C et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994; 37: 644-652.
11. di Giovine FS, Takhsh E, Blakemore AI, Duff GW. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet 1992; 1: 450.
12. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396-402.
13. Di Giovine FS, Cork MJ, Crane A, Mee JB, Duff GW. Novel genetic association of an IL-1B gene variation at +3953 with IL-1 beta protein production and psoriasis. Cytokine 1995; 7: 606 (Abstr. A665).
14. Demeter J, Messer G, Ramisch S et al. Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies. Cytokines Mol Ther 1996; 2: 239-242.
15. Clay FE, Tarlow JK, Cork MJ, Cox A, Nicklin MJ, Duff GW. Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment. Hum Genet 1996; 97: 723-726.
16. Bidwell J, Keen L, Gallagher G et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999; 1: 3-19.
17. Heresbach D, Alizadeh M, Dabadie A et al. Significance of interleukin-1beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. Am J Gastroenterol 1997; 92: 1164-1169.
18. Bioque G, Crusius JB, Koutroubakis I et al. Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol 1995; 102: 379-383.
19. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977; 18: 481-491.
20. van der Heijde DM. Radiographic imaging: the 'gold standard' for assessment of disease progression in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39 (Suppl 1): 9-16.
21. van Zeben D, Hazes JM, Zwinderman AH et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a follow up study. Arthritis Rheum 1991; 34: 822-830.
22. Corbett M, Dalton S, Young A, Silman A, Shipley M. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 1993; 32: 717-723.
23. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-IRa) is an acute-phase protein. J Clin Invest 1997; 99: 2930-2940.
24. Cantagrel A, Navaux F, Loubet-Lescoulie P et al. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999; 42: 1093-1100.
25. Seidl C, Donner H, Fischer B et al. CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens 1998; 51: 62-66.
26. Barton A, Myerscough A, John S, Gonzalez-Gay M, Ollier W, Worthington J. A single nucleotide polymorphism in exon 1 of cytotoxic T-lymphocyte-associated-4 (CTLA-4) is not associated with rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 63-66.
27. Cox A, Camp NJ, Cannings C et al. Combined sib-TDT and TDT provide evidence for linkage of the interleukin-1 gene cluster to erosive rheumatoid arthritis. Hum Mol Genet 1999; 8: 1707-1713.
28. Jouvenne P, Chaudhary A, Buchs N, di Giovine FS, Duff GW, Miossec P. Possible genetic association between IL-1α gene polymorphism and the severity of arthritis. Eur Cyt Netw 1999; 10: 33-36.
29. Stokkers PC, van Aken BE, Basoski N, Reitsma PH, Tytgat GN, van Deventer SJ. Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease. Gut 1998; 43: 33-39.
30. Kornman KS, Crane A, Wang HY et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol 1997; 24: 72-77.
31. Huang D, Pirskanen R, Hjelmstrom P, Lefvert AK. Polymorphisms in IL-1beta and IL-1 receptor antagonist genes are associated with myasthenia gravis. J Neuroimmunol 1998; 81: 76-81.
32. Saxne T, Di Giovine FS, Heinegard D, Duff GW, Wollheim FA. Synovial fluid concentrations of interleukin-1 beta and proteoglycans are inversely related. J Autoimmun 1988; 1: 373-380.
33. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99: 303-310.
34. Mandrup-Poulsen T, Pociot F, Molvig J et al. Monokine antagonism is reduced in patients with IDDM. Diabetes 1994; 43: 1242-1247.
35. Dionne S, D'Agata ID, Hiscott J, Vanounou T, Seidman EG. Colonic explant production of IL-1 and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol 1998; 112: 435-442.
36. Schaid DJ, Sommer SS. Genotype relative risks: methods for design and analysis of candidate-gene association studies. Am J Hum Genet 1993; 53: 1114-1126.
37. Freidel AC, Betuel H, Gebuhrer L, Farre A, Lambert J. Cellular and serological subtypes of HLA-DR2. Tissue Antigens 1987; 29: 129-140.
38. Jouvenne P, Vannier E, Dinarello CA, Miossec P. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum 1998; 41: 1083-1089.